

Affiliated to: SUP/(Should) (Approved by - AKTE)New Delhi) & PC(New Oath)
Register - Under USC 219)

700	600 T	A.Tail	
- 500	981		
100	98 °		
- 10	= 1	1 backing	chubbake:

INDORE INSTITUTE OF PHARMACY, INDORE

3.3.3 Number of books and chapter is edited volume/ books published and paper published in national / international conferences proceedings as per teacher during published per teacher the year

		Name of the apathor/s	Department of the teacher	Name of Book			ISBN number	Link to the recognition in UGC enlistment of the Journal /Digital Object Identifier (doi) number			
S. No	Title of chapter/ Book					Year of publicati on		Link to website of the Book	Link to Chapter	Is it listed in UGC Care list/Scopus /Web of Science/ot her, mention	
Ē	A Textbook of Pharmacology-III (Book)	Dr Praveen Sharma, Dr Santosh D. Ghule, Dr. Pritesh Paliwal, Dr. Upendra Singh Bhadoriva	Pharmacology	A Textbook of Pharmacology-III	NA.	2023	978-81-19425-12-9	www.shinebook.publishin g.com	NA	No	
2	Practical Handbook of Pharmacology-I (Book)	Mr. Rohit Dhoke, Dr. Praveen Sharma, Mr. Ajay Bhagwat, Dr. Santosh Ghule	Pharmacology	Practical Handbook of Pharmacology-1	NA	2023	978-93-5735-226-0	www.pritampublication.com	NA.	No	
3	Physical Pharmaceutics II (Book)	Dr Dinesh Kumar Mishra, Ms Nayany Sharma, Mr Kuldeep Vinchurkar	Pharmaceutics	Physical Pharmaceutics II	NA	2023	978-81-963767-3-0	www.gyanpublications.c	NA	No	
4	"New Anti-Diabetic Drugs for Treatment of Type-II Diabetes: A Comprehensive Overview" (Chapter)	Rekha Bisht	Phermacy Practice	Recent Research Trends in Pharmaceutical Science		2023	978-93-5834-010-5	www.integratedpublicati ons.in			
5	Artificial intelligence (AI) and Machine Learning in the Treatment of Various Diseases	Dr. Rupesh K. Gautam	Pharmacology	Computational Approaches in Drug Discovery Development and Systems pharmacology		2023	978-0-323-99137-7	https://www.sciencedirect.com/book/9780323991 377/computational- approaches-in-drug- discovery-development- and-systems- pharmacology	https://doi.org/10.10 16/8978-0 323- 99137- 7.00010-1	Scopus	
6	Pharmacophere Modeling	Dr. Rupesh K. Goutam	Pharmacology	Computational Approaches in Drug Discovery. Development and Systems pharmacology		2023	978-0-323-99137-7	https://www.sciencedirect.com/book/9780323991 377/computational-approaches-in-drug- discovery-development- and-systems- pharmacology	https://doi. org/10.10 16/B978-0 323- 99137- 7.00004-6	Scopus	

Principal Indore Institute of Pharmacy. INDORE (M.P.)



Indore Institute of Pharmacy Affidated to A STON (Shaped | Agencied by - ANCE) New Deby & P.C. (Trees Deby) Agency - Under USC 2017.

									-
7	New Drug Discovery Pipeline	Dr Rupesh K Gautam	Pharmacology	Computational Approaches in Drug Discovery, Development and Systems pharmacology	2023	978-0-323-99137-7	277/computational- approaches-in-drug- discovery-development- and-systems- pharmacology	https://doi. org/10.10 16/B978-0- 323- 99137- 7.00003-4	Scopus
8	Artificial Intellegence and Machine Learning- Based New Drug Discovery Process with Molecular Modeling	Dr. Rupesh K. Gautam	Pharmacology	Bioinformatics Tools for Pharmaceutical Drug Product Development	2023	978-1119-865-117 f	https://onlinelibrary.wile y.com/doi/book/10/1002/ 9781119865728	https://doi. org/10.10 02/978111 9865728.c h2	Scopus
9	Biobased materials in nutraceuticals	Dr Rupesh K. Gautam	Pharmacology	Advanced Applications of Buohased Maternals	2023	978-0-323-91677-6	https://www.sciencedire ct.com/book/978032391 6776/advanced- applications-of-biobased- materials	https://do i.org/10.1 016/8978- 0-323- 91677- 6.00003-9	Scopus
10	Symbiotics for colon cancer	Dr. Rupesh K. Gautam	Pharmacology	Synbiotics for the Marragement of Cancer	2023	978-981-19-7550- 9_5	https://link.springer.com/ chapter/10.1007/978-981 19-7550-9_5	10.1007/97 8-981-19- 7550-9_5	Scopia
11	Currents Updates in Breast Cancer Drug	Dr. Rupesh K. Gautam	Pharmacology	Drug and Therapy Development for Triple Negative Breast Cancer	2023	978-352-73517-56	hups://onlinelibrary.wile y.com/doi/book/10.1002/ 9783527841165	https://doi. org/10.10 02/978352 7841165.c h15	Scepu
12	Artificul intelligence-driven décisions in breast cancer diagnosis	Dr. Rupesh K. Gautam	Pharmacology	Drug and Therapy Development for Triple Negative Breast Cancer	2023	978-352-73517-56	https://onlinelibrary.wile y.com/doi/book/10.1002/ 9783527841165		Scopu
13	Establishing nanotechnology-based drug development for triplenegative breast cancer treatment	Dr Rupesh K Gautam	Pharmacology	Drug and Therapy Development for Triple Negative Breast Cancer	2023	9783-5273-5175-6	https://onlinelibrary.wile y.com/doi/book/10.1002 9783527841165		Scopu
14	Recent Advancement of Nanotherapeutics to Treat Breast Cancer	Dr Rupesh K. Gautam	Pharmacology	Drug and Therapy Development for Triple Negative Breast Cancer	2023	978-35-27351-75-6	https://onlinclibrary.wile y.com/doi/book/10.1002 9783527841165		Scop

Principal Indore Institute of Pharmacy, INDORE (M.P.)



Indore Institute of Pharmacy Affidated to A STON (Shaped | Agencied by - ANCE) New Deby & P.C. (Trees Deby) Agency - Under USC 2017.

15	EXIT EXAM FOR DIPLOMA IN PHARMACY	NADEEM FAROOQUI	PHARMACEUTICS	EXIT EXAM FOR DIPLOMA IN PHARMACY	NA	2023	978-81-964986-2-7	https://www.amazon.in/ Guide-Diploma- Pharmacy-EXIT- EXAM/dp/BOCHMZ86Z L/ref=s_1_Perid=UY3 QLBA5X4Z&keywords =diploma+exam+exit+bo ok+gyan+publication&oi	NO
16	Practical lab menual of human anatomy and physiology	Dr. Praveen Sharma Kuldeep Vinchurkar Rohit Sahu	нар-і	Practical lab manual of human anatomy and physiology		2023	f 978-620-677943-8	https://www.amazon.co.j p //Practical-Manual- Human -Anatomy-Physiology/dp /6206779432	No
17	Text book of pharmacology-III	Dr. Nikl,esh Birla Ms. Navneel Kaur Dr. Praveen Sharma Mr. Manvendra	Pharmacology-III	Text book of pharmacology-HI		2023	979-889-1866-317	https://www.flipkart.co m/text-book- pharmacology- iii/p/itm708e9758a01cc ?pid=9798891866317&c mpid=product.share.pp & refid=PP a3d1bc40-	No
18	Nanotherspectics for breast cancer using metal nanocomposites	Dr. Rupesh K. Gautam	Pharmacology	Metal Nanocomposite s in Nanotherapeutic s for Oxidative Stress-Induced Metabolic Disputers		2023	978-103-262-11-35	4095-49d2-ac08- littps://www.laytortranci- scom/books/dit/10.120 1.197810326/21135/metal- nanocomposites- nanotherapeutics- oxidative-stress-induced- metabolic-disorders- appoints.	Scop
19	Nanotherapeutics for liver cancer using metal nanocomposites	Dr. Rupesh K. Gautam	Pharmacology	Nanocomposite s in Nanotherspeutic s for Oxidative Stress-Induced Metabolic Dicordage		2023	978-103-262-1135	https://www.taylorfranc is.com/books/edit/10.12 01/9781032621135/met al-nanocomposites- nanotherapeutics oxidative-stress-induced- metabolic-disorders-	Scop
39	Everything you need to Know about high fat diets	Dr. Rupesh K. Gautarn	Pharmacology	NOVA Publisher		2023	979-8-88697-601-	NOVA Publisher	



Principal Indore Institute of Pharmacy, INDORE (M.P.)



PHARMACOLOGY III

AS PER PCI REGULATIONS

THIRD YEAR B.PHARM

AUTHORS

Dr. Praveen Sharma Dr. Santosh Ghule Dr. Pritesh Paliwal Dr. Upendra singh Bhadoriya

DAG

Indore Institute of Pharmocy, INDORE (M.P.)



Affiliated to SDPV[Shagal] (Appreced by -AKTE]New Debi | & PCI/New Deb

First published by Shine Book Publishing 29/T, Jabadapara, Sarkanda Bilaspur, Chattisgarh 495001 Copyright ©Dr. Praveen Sharma, Dr. Santosh Ghule, Dr. Pritesh Paliwal, Dr. Upendra singh Bhadoriya

No part of this book may be reproduced, or stored in a retrieval system, or transmitted any form or any means, electronic, photocopying, recording, or otherwise, without expression of the copyright owner.

ISBN:978-81-19425-12-9

MRP: Rs.360/-

Thisbookcannotbecopiedinanyformat, resold, or otherwise transferred by digital format another through upload to a file sharing peer to peer program, for free or for a fee, or a prize in any contest. Such action is illegal and in violation of International Copyright L Distribution of this book, in whole or in part, online, offline, in print or in any way or a other method currently known or yet to be invented, is forbidden. If you have this book eBook format and do not want it anymore, you must delete it from your computer.



Principal Indore Institute of Pharmacy, INDORE (M.P.)





BP602T. PHARMACOLOGY-III (THEOTY)

SILENT FEATURE

Pharmacology

Pharmacological drug screening is the sequential testing of new chemical entities or extracts from biological material in isolated organs with subsequent testing on whole experimental animals. Screening Methods in Pharmacology focuses on methods of screening groups for pharmacological activities and discussions on the organization of screening programs. This book provides a descriptive approach detailing the CPCSEA, OECD and ICH guidelines to follow when screening new drug classes. It also provides a brief overview of bioassays and research methodology along with various experimental animal screening models for various diseases. This book will serve as a reference manual for graduate students in pharmacy and life sciences.

Distinctive features

- 1. Beneficial for pharmacy and life sciences graduates and researchers. 2. Provides various experimental animal screening models for various diseases.
- 3. Provides special guidelines for the use of animals during experimental protocols. 4. Provides a brief description of the bio assay.



Principal
Indore Institute of Pharmacy,
INDORE (M.P.)



Preface

Itgivesusimmensepleasuretopresentthe"FirstEdition"ofthisbook, whichisdedicatedtostudents and faction of this country. This book is designed by a processed in accountry. of B. Pharma institutes of this country. This book is designed by a processed in accordance w of B. Pharma institutes of this country. This book is designed by a processed in accordance we requirement of the syllabus "Pharmacology-III" of the third year (6th semester) B. Pharmacothera course prescribed in the field "Bachelor of Pharmacy (B. Pharm) Course Regulations 201

Sincere efforts have been made to present the experimental details along with the preliminar experimental aspects, i.e. vehicles election, drugdissolution and rational volumes election, preparation of the experiment pharmacolar with examples used in the experiment pharmacolar description of solution and working standards with examples used in the experiment pharmacology. Most exper are described by giving examples with intent scaffolding experimental procedures trials during pr

Basic concepts and basic principles were discussed for each experiment, to make the practical understandingtheobjective experiments. Someexperimentstakenwith(ruidelines, illustrationobservationalvalues for several experiments, measures overcomingerrors.

> Indore Institute of Pharmacy, INDORE (M.P.)





BP602 T. PHARMACOLOGY-III (theory)

45 hours

The subject is intended to impart basic knowledge about various aspects (classification, mechanism of action, therapeutic effects, clinical use, side effects and contraindications) of drugs affecting the respiratoryandgastrointestinalsystem, infectious diseases, immunopharmacology, and further, emphasis on the principles of toxicology and chronopharmacology.

Objectives: After completing this course, the student should be able to:

- 1, understand the mechanism of action of the drug and its importance in the treatment of various infectious diseases
- understand the principles of toxicology and the treatment of variouspoisoningsand appreciate the correlation of pharmacology with relatedmedicalsciences.
 Coursecontent:

UNIT-I 10 hrs

1. Pharmacology of drugs acting on therespiratorysystem

Antiasthmatic drugs
Medicines used in the treatment of COPD
Expectorants and antitussives
Nasal decongestants
Respiratory stimulants

2. Pharmacology of drugs acting on thegastrointestinaltract

Antiulcer substances.
Medicines for constipation and diarrhea.
Stimulants and appetite suppressants.
Digestives and carminatives.
Emetics and antiemetics.

UNIT-II 10 hrs 3. Chemotherapy

General principles of chemotherapy.
Sulfonamides and co-trimoxazole.
Antibiotics— Penicillins, cephalosporins, chloramphenicol, macrolides, quinolones and fluoroquinolines, tetracycline andaminoglycosides

UNIT III 10 Hours
3. Chemotherapy


Antitubercular substance b.Antileprotic substances



Principal

Indore Institute of Pharmacy, INDORE (M.P.)











Affiliated to: SGPV[Shapal] (Appreced by - AKTR[New Debt] & PCI/New Oath








Affiliated to : 80PV[Shoust] (Approved by - AKTE]New Debt] & PCI/New Onbi











Affiliated to : 80PV[Shopal] (Approved by - AKTE]New Debt) & PCI/New Debt

Published By: Integrated Publications

Integrated Publications
H. No. - 3 Pocket - H34, Sector - 3,
Rohini, Delhi-110085, India
Phone No. - 9911215212
Email - printintegrated@gmail.com

Chief-Editor: Dr. Kratika Daniel Co-Editor: Prof. M. Deepa

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

The responsibility for facts stated, opinion expressed or conclusions reached and plagiarism, if any, in this book is entirely that of the author. So, the views and research findings provided in this publication are those of the author/s only. The Editor & Publishers are in no way responsible for its contents.

© Integrated Publications TM

Publication Year: 2023

Pages: 125

ISBN: 978-93-5834-010-5

Book DOI: https://doi.org/10.22271/int.book.300

Price: ₹716/-



Contents

Chapters 1. Microbiological Quality Control in Pharmaceutical Industry (Shalini Sehgal and Sunita Aggarwal) 2. New Anti-Diabetic Drugs for Treatment of Type-II Diabetes: A Comprehensive Overview (Rekha Baht) 3. Anti-Cancer Drugs Screening Methods and their Recent

- Solid Dispersion: An Application for Enhancing Bioavailability 45-67 (Sriranga T., Sreenivasa G.M., Anni Nandisha, Naveen S. Banakar, K.S. Anusha and Chetan Kumar Vasnad)
- 5. Antibacterial Activity of Calystegia sepium, Dacryodes edulis and Carica papaya and their Synergistic Effects with Amoxicillin and Serum 69 (Jean-De-Dieu Tamokou, Jules-Arnaud Mboutchom Fosso, Abdel Jélil Njouendou, Steve Endeguele Ekom c-d Irene Chinda Kengne)
- Autosomal Dominant Polycystic Kidney Disease
 Opr. Cyril Sajan, Dr. Varunsingh Saggu, Dr. Rajesh Hadia, Dr. Hemraj Singh
 Rajput, Dilsar Gohil, Foram Bhatt and Krupa Joshi)
- 7. Green Metrics for Analytical Techniques
 (Dr. Yenduri Suvarna and Dr. Naga Prashant K)

Principal Indore Institute of Pharmacy, INDORE (M.P.)

107-125



Chapter - 2

New Anti-Diabetic Drugs for Treatment of Type-II Diabetes: A Comprehensive Overview

Rekha Bisht

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is characterized by an escalation in blood sugar levels. More than 400 million people are affected by this life-threatening disease worldwide and it is estimated that there will be around 640 million people with T2DM worldwide in 2040. It is of utmost importance to bring in lifestyle changes to attain significant metabolic control in diabetes along with appropriate pharmacological treatment. To have significant control of blood sugar levels, doctors should be familiar with the recent advancement in various types of anti-diabetic drugs available in the market. The physician should focus on the selection of the most effective, safe, and well-tolerated anti-diabetic drugs to accomplish the goal of glycemic control and to avoid the long-term complication of diabetes such as retinopathy, nephropathy, etc. The prime emphasis of the present review is to focus on the gamut of currently available anti-diabetic drugs for the management of T2DM and also present a brief overview of their mechanism of action in controlling blood sugar

Keywords: Type 2 diabetes mellitus, macrovascular complications, microvascular complication

Introduction

Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting directly from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion [1, 2, 3] (Blair M, 2016; Bisht R, 2019; Yitbarek GY, 2021).

The effects of diabetes mellitus include long-term damage, dysfunction, Indore Institute of Pharmand failure of various organs, Diabetes mellitus may present with characteristic symptoms such as thirst, polyuria, blurring of vision and



INDORE (M.P.)



Computational Approaches in Drug Discovery. Development and Systems Pharmacology

2023, Pages 139-158

Chapter 4 - Artificial intelligence (AI) and machine learning in the treatment of various diseases

Pooja Mittal ^a, Rajat Goyal ^b, Ramit Kapoor ^c, Rupesh Kumar Gautam ^d

Show more >

% Share 55 Cite ∃ Outline

https://doi.org/10.1016/B978-0-323-99137-7.00010-1 > Get rights and content >

Abstract

Artificial Intelligence (AI) and Machine Learning (ML) have significant ability in improving the health care research. The adoption of Al-driven technologies can aid in the elimination of health disparities and reduce the load on healthcare systems. It is being implemented in various sectors such as pharmaceutical drug discovery, development, drug repurposing, improved drug therapy, clinical trails, and drug designing. The use of Al in these field can enhance the precision and accuracy and can reduce the human errors and make the work easier and more convenient. By using Al in drug designing and development, we can easily identify the targets and can develop the target susceptible drugs only, which will reduce the wastage of time d money. Computer systems are clearly speedier when it comes to calculations and analytic skills, yet they could not indeed make judgments on their own, since they lack the capacity to do so. Today, Al has a broad range of usage in nearly every sector, which appears to be beneficial and is displacing human professions that may be deemed unfavorable.

Recommended articles

References (0)

Cited by (0) IQAC View full text

Indore Institute of Phorn INDORE (M.P.)



Computational Approaches in Drug Discovery, Development and Systems Pharmacology

2023, Pages 159-182

Chapter 5 - Pharmacophore modeling

Maheshkumar Borkar a, Arati Prabhu a, Abhishek Kanugo b, Rupesh Kumar Gautam

Show more >

∷ Outline | % Share 55 Cite

https://doi.org/10.1016/8978-0-323-99137-7.00004-6 > set rights and content > 5

LOAG

Abstract

Pharmacophore modeling is an important part of "computer-aided drug design (CADD)" and has led to numerous successful research outcomes. It contributed significantly in the rational drug design approach. The pharmacophore model abstracts crucial structural attributes of a molecule that are crucial for pharmacological activity, along with their relative positions in three-dimensional space. There are various ligand- and structure-based methods that have been developed for improved pharmacophore modeling and fruitfully applied in de novo design, lead optimization, virtual screening, off-target and target identification, side effect, and ADME-tox modeling. Current chapter gives a comprehensive impression of pharmacophore modeling, focus on various types of pharmacophores, methodology development, and its vast spectrum of applications.

Recommended articles

References (0)

Cited by (1)

PharmacoNet: Accelerating Large-Scale Virtual Screening by Deep Pharmacophore Modeling

2023, arXiv


View full text

INDORE (M.P.)




NDOR

Indore Institute of Pharmacy







Drug development is a time-consuming, expensive and extremely risky procedure. Up to 90% of drug concepts are discarded due to challenges such as safety, efficacy and toxicity resulting in significant losses for the investor. The use of artificial intelligence (AI), namely machine learning and deep learning algorithms, to improve the drug discovery process is one technique that has arisen in recent years. All has been effectively used in drug discovery and design. This chapter includes these machine learning approaches in depth, as well as their applications in medicinal chemistry. The current state-of-the-art of AI supported pharmaceutical discovery is discussed, including applications in structure and ligand-based virtual screening, *de novo* drug design, drug repurposing and factors related, after introducing the basic principles, along with some application notes, of the various machine learning algorithms. Finally, obstacles and limits are outlined, with an eye towards possible future avenues for AI-supported drug discovery and design.



Computational Approaches in Drug Discovery, Development and Systems Pharmacology

2023, Pages 139-158

Chapter 4 - Artificial intelligence (AI) and machine learning in the treatment of various diseases

Pooja Mittal a, Rajat Goyal b, Ramit Kapoor c, Rupesh Kumar Gautam d

Show more >

https://doi.org/10.1016/8978-0-323-99137-7.00010-1 7 Get rights and content 71

Abstract

Artificial Intelligence (AI) and Machine Learning (ML) have significant ability in improving the health care research. The adoption of Al-driven technologies can aid in the elimination of health disparities and reduce the load on healthcare systems. It is being implemented in various sectors such as pharmaceutical drug discovery, development, drug repurposing, improved drug therapy, clinical trails, and drug designing. The use of AI in these field can enhance the precision and accuracy and can reduce the human errors and make the work easier and more convenient. By using AI in drug designing and development, we can easily identify the targets and can develop the target susceptible drugs only, which will reduce the wastage of time and money. Computer systems are clearly speedier when it comes to calculations and analytic skills, yet they could not indeed make judgments on their own, since they lack the capacity to do so. Today, Al has a broad range of usage in nearly every sector, which appears to be beneficial and is displacing human professions that may be deemed unfavorable.

Recommended articles

References (0)


Cited by (0)

Indore Institute of Pharmacy,


View full text



Indore Institute of Pharmacy Application of Application (Application of Application (Application of Application of Application









_11a :er

Artificial Intelligence-Driven Decisions in Breast Cancer Diagnosis

Amit Gangwal, Rupesh K. Gautam

MAG

300k Editor(s):Pravin Kendrekar, Vinayak Adimule, Tara Hurst

First published: 16 June 2023

https://doi.org/10.1002/9783527841165.ch8

Summary

Artificial intelligence (AI) is a disruptive innovation, involving the development and deployment of algorithms to classify data, and to find the abstract relationships between different data points. Al, its subtype machine learning (ML), and advanced version of ML that is deep learning (DL) have shown commendable progress in the last decade in various fields like marketing, banking, ecommerce platforms, streaming platforms, self-driving cars, retrosynthesis of chemicals, clinical trials, drug discovery, and others. This remarkable change has been attributed to the availability of high-speed internet, the internet of things, the huge amount of data, and most importantly cuttingedge computation tools like graphics processing units (GPUs), referred to as GPUs. Although the success of Al in medical imaging is limited initially, now stakeholders are focusing on the deployment of full-fledged AI systems by riding on the success of convolutional neural networks (CNNs) in other areas like image identification through computer vision, generation of an entirely new set of images, and videos based on training and testing datasets. Breast cancer is one of the most common cancers in women worldwide. Various diagnostic tools are there to conform positive or negative cases, still, sure-shot reliance on these tools is doubtful owing to unintentional flaws in scan interpretation by radiologists. Here, in such circumstances, experts are now leveraging AI to aid humans with faster, accurate, and bias-free interpretation much to the relief of patients. In this chapter, how Al is shaping and redefining entire mammogram interpretation has been elaborated esides throwing light on classical tools for diagnosis and interpretation of breast cancer.

Harbeck, N., Penault-Llorca, F., Cortes, J. et al. (2019). Breast cancer. Nat. Rev. Dis. Primers 5:66.

Yoon, J.H. and Kim, E.K. (2021). Deep learning-based artificial intelligence for mammography. *Korean J. Radiol.* 22 (8): 1225.


Myers , E.R. , Moorman , P. , Gierisch , J.M. et al. (2015). Benefits and harms of breast cancer screening: a systematic review . *JAMA* 314 (15): 1615 – 1634.

Indore Institute of Pharmacy, INDORE (M.P.)



A STATE OF THE REAL PROPERTY.

- Hapter >





Devesh U. Kapoor, Rajat Goyal, Rajiv R. Kukkar, Rupesh K. Gautam

Book Editor(s): Pravin Kendrekar, Vinayak Adimule, Tara Hurst

First published: 16 June 2023

https://doi.org/10.1002/9783527841165.ch3

Summary

The second biggest worldwide death is due to breast cancer; approx. 8.6 million were diagnosed with breast cancer in 2018. With this intensifying global burden, in the twenty-first century cancer prevention in females is one of the utmost thoughtful health challenges. Regardless of improvements in breast tumor therapeutic approaches, the quick recurrence of tumors and netastasis in patients exhibited that people develop resistance against the chemotherapeutic medication. Nanotechnology provides a noteworthy alternative to delivering anticancer drugs safely and efficiently. With the help of various nanoformulations, one can target the specific organ, the accumulation of drugs at the specific target site, and diminish the cytotoxicity. An effective therapeutic approach to treating breast cancer involves the conjugation of targeting ligands with nanocarriers. The nano nutraceuticals also showed promising results against breast cancer treatment. The growth in nanotherapeutics offers significant potential against breast cancer therapies and pharmaceutical research.

Reference

Pripoipal Indore Institute of Pharmacy, INDORE (M.P.)

(ram, M., Iqbal, M., Daniyal, M., and Khan, A.U. (2017). Awareness and current knowledge of breast cancer. *Biol. Res.* 50 (1): 1 – 23. https://doi.org/10.1186/s40659-017-0140-9.


Kamaruzman , N.I. , Aziz , N.A. , Poh , C.L. , and Chowdhury , E.H. (2019). Oncogenic signaling in tumorigenesis and applications of siRNA nanotherapeutics in breast cancer . *Cancers* 11 (5): 632 . https://doi.org/10.3390/cancers11050632 .

Nazih , H. and Bard , J.M. (2020). Cholesterol, oxysterols and LXRs in breast cancer pathophysiology . *Int. J. Mol. Sci.* 21 (4): 1356 . https://doi.org/10.3390/ijms21041356 .


Batakurki , S.R. , Adimule , V. , Pai , M.M. et al. (2022). Synthesis of Cs–Ag/Fe $_2$ O $_3$ nanoparticles using Vitis




by - ACTESNow Delhi) & PCI(New Delhi)









































Affiliated to : 80PV[Shopal] (Approved by - AKTE]New Debt) & PCI/New Debt

